New Data for florbetaben F18 from Piramal Imaging
October 2013 — Results from five studies evaluating Piramal Imaging’s PET amyloid imaging agent, florbetaben F18, were presented at Alzheimer’s Association International Conference (AAIC). “The studies presented at this year’s conference continue to reinforce the strength of the florbetaben F18 development program. We are hopeful CMS will consider the increasing evidence why beta-amyloid imaging is a medically necessary diagnostic tool for appropriate Medicare populations,” said Dr. Ludger Dinkelborg, Director of the Board, Piramal Imaging SA. Florbetaben is under review by the FDA and European Medicines Agency for use in the visual detection of beta-amyloid in the brains of adults with cognitive impairment who are being evaluated for Alzheimer’s disease and other causes of cognitive decline. Look for more coverage in next month’s edition of Practical Neurology.